35166-20-2

Usage

Uses

Used in Pharmaceutical Research:
Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)(9CI) is utilized as a key component in the development of pharmaceuticals due to its distinctive structure and the range of biological activities it can exhibit. Its presence in drug formulations can contribute to the modulation of various physiological processes, thereby addressing specific medical needs.
Used in Chemical Synthesis:
In the chemical industry, Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)(9CI) serves as an intermediate in the synthesis of more complex organic compounds. Its unique functional groups and structural features make it a versatile building block for creating a variety of chemical products, including advanced materials and specialty chemicals.
Used in Analytical Chemistry:
Ethanone, 1-(3,5-dimethyl-4-isoxazolyl)(9CI) can also be employed in analytical chemistry as a reference compound or as part of a calibration standard. Its distinct chemical properties allow it to be used in the development and validation of analytical methods, ensuring accurate measurements and reliable results in various chemical analyses.

InChI:InChI=1/C7H9NO2/c1-4-7(5(2)9)6(3)10-8-4/h1-3H3

Upstream product

• 546-88-3 acetylhydroxamic acid 
• 123-54-6 acetylacetone 
• 2510-36-3 3,5-dimethyl-4-isoxazolecarboxylic acid 
• 917-54-4 methyllithium 
• 917-64-6 methyl magnesium iodide 
• 31301-46-9 4-cyano-3,5-dimethylisoxazoline 
• 1223452-45-6 N-methoxy-N-methyl-3,5-dimethylisoxazole-4-carboxamide 
• 75-16-1 methylmagnesium bromide 
• 31301-45-8 3,5-dimethylisoxazole-4-carbonyl chloride 
• 59402-44-7 1-(3,5-dimethylisoxazol-4-yl)ethanol 
• 54593-26-9 3,5-dimethyl-1,2-oxazole-4-carbaldehyde 
• 19788-36-4 4-hydroxymethyl-3,5-dimethylisoxazole 
• 56328-87-1 methyl 3,5-dimethylisoxazole-4-carboxylate 

Downstream Products

• 23000-12-6 1-(2,5-dimethyloxazol-4-yl)ethanone 
• 117525-34-5 4-(1-hydroxy-1-methyl)ethyl-3,5-dimethylisoxazole 
• 127916-13-6 1-(2-Acetyl-3-methyl-2H-azirin-2-yl)-ethanone 
• 85094-04-8 4-cinnamoyl-3,5-dimethylisoxazole 
• 1421838-38-1 methyl 2-(4-(2-(3,5-dimethylisoxazol-4-yl)-2-hydroxyethoxy)phenyl)acetate 
• 1421838-41-6 2-(4-(2-(3,5-dimethylisoxazol-4-yl)-2-oxoethoxy)phenyl)-N-((2,4-dimethylphenyl)(phenyl)methyl)acetamide 
• 1421837-32-2 C₃₀H₃₂N₂O₄ 
• 1421838-42-7 methyl 2-(1-(3,5-dimethylisoxazol-4-yl)-2-(4-(2-(((2,4-dimethylphenyl)(phenyl)methyl)amino)-2-oxoethyl)phenoxy)ethoxy)-2-methylpropanoate 
• 1421837-91-3 C₃₄H₃₈N₂O₆ 
• 1421838-37-0 methyl 2-(4-(2-(3,5-dimethylisoxazol-4-yl)-2-oxoethoxy)phenyl)acetate 
• 1585970-67-7 C₂₀H₂₅N₃O₃S 
• 1585970-68-8 C₂₀H₂₅N₃O₃S 
• 1585970-69-9 C₁₉H₂₄F₂N₂O₃S 
• 1585970-70-2 C₁₉H₂₄BrFN₂O₃S 

Relevant academic research and scientific papers

Synthesis and biological evaluation of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives as novel potent transforming growth factor-β type 1 receptor inhibitors

Inhibition of transforming growth factor β (TGF-β) type 1 receptor (ALK5) provides a feasible approach for the treatment of fibrotic diseases and malignant tumors. In this study, we designed and synthesized a new series of 4-(pyridin-4-oxy)-3-(3,3-difluorocyclobutyl)-pyrazole derivatives, and evaluated biologically as TGF-β type 1 receptor inhibitors. The most potent compound 15r inhibited the ALK5 enzyme and NIH3T3 cell viability with IC50 values of 44 and 42.5 nM, respectively. Compound 15r also displayed better oral plasma exposure and excellent bioavailability than LY-3200882, and in vivo inhibited 65.7% of the tumor growth in a CT26 xenograft mouse model.

Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents

By targeting the flap backbone of the BACE1 active site, we discovered 6-dimethylisoxazole-substituted biaryl aminothiazine 18 with 34-fold improved BACE1 inhibitory activity over the lead compound 1. The cocrystal structure of 18 bound to the active site indicated two hydrogen-bond interactions between the dimethylisoxazole and threonine 72 and glutamine 73 of the flap. Incorporation of the dimethylisoxazole substitution onto the related aminothiazine carboxamide series led to pyrazine-carboxamide 26 as a very potent BACE1 inhibitor (IC50 1 nM). This compound demonstrated robust brain Aβ reduction in rat dose-response studies. Thus, compound 26 may be useful in testing the amyloid hypothesis of Alzheimer's disease.

Pyrimidinone Derivatives as Antimalarial Agents

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION

Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 al-kyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, halo C1-4 alkyl, CN, C1-C6, alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -SO2C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, ben-zyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4 alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z to-gether can be absent

PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS

The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n = 0 or 1 and R2 is a methyl group when n = 0 and a hydrogen atom when n = 1. Process for the preparation thereof and therapeutic use thereof.

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-reiated orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.

Photochemistry of 4-Acylisoxazoles

The photochemistry of 4-acylisoxazoles 4, 5, 13, 14, and 17 was investigated in an effort to clarify literature contradictions and anomalies and to provide a more detailed picture of the nature and number of intermediates involved in photoreactions of these systems.In contrast to a previous report on the photorearrangement of 14, both oxazoles expected from a 2H-azirine intermediate have been observed.Wavelength studies of 5 and the derived 2H-azirine 10 revealed evidence for the involvement of at least two distinct product-forming intermediates.The results of quantum yield and laser photolysis measurements for ketones 4, 14, and 17 have been interpreted in terms of rapid openings of triplet states to form diradical-like intermediates coupled with efficient reclosures (70-99percent).

Reaction of Isoxazoles and Isoxazolium Salts with Organometallic Reagents. Synthesis of Dihydroisoxazoles

2,3- 2,5- and 4,5-Dihydroisoxazoles have been selectively synthesized by reaction of isoxazoles with organo-lithium, -magnesium, and -aluminium reagents.Moreover, the reaction of benzoisoxazolium salts with highly basic organolithium compounds leads to ph

Isoxazolyl indolamines

This disclosure describes compounds of the formula STR1 where R1 represents hydrogen, fluoro, chloro, lower alkyl having 1 to 4 carbon atoms or lower alkoxy having 1 to 4 carbon atoms, and R2 represents hydroxy, and R3 and R4 each independently represent lower alkyl as defined above, or R3 and R4 together with N represent STR2 wherein n is 1, 2, or 3, and R5 and R6 each independently represent hydrogen or lower alkyl as defined above, and R7 represents lower alkyl as defined above, or a pharmaceutically acceptable acid addition salt thereof, which are useful as anti-diabetic agents, in particular as hypoglycemic agents and inhibiting or impeding postprandial hyperglycemia.